A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung

• Status: Recruiting
• Trial end date: 2024-09-30

Summary

The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.

• Phase: Phase 3

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Carboplatin; Docetaxel; Nivolumab; Paclitaxel; Pemetrexed